Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 December 2021Website:
http://www.allarity.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:49:01 GMTDividend
Analysts recommendations
Institutional Ownership
ALLR Latest News
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.
NEW YORK, Nov. 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline.
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06952, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), of the important November 12, 2024 lead plaintiff deadline. So what: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline.
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”).
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Allarity securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period").
What type of business is Allarity Therapeutics?
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
What sector is Allarity Therapeutics in?
Allarity Therapeutics is in the Healthcare sector
What industry is Allarity Therapeutics in?
Allarity Therapeutics is in the Biotechnology industry
What country is Allarity Therapeutics from?
Allarity Therapeutics is headquartered in United States
When did Allarity Therapeutics go public?
Allarity Therapeutics initial public offering (IPO) was on 21 December 2021
What is Allarity Therapeutics website?
https://www.allarity.com
Is Allarity Therapeutics in the S&P 500?
No, Allarity Therapeutics is not included in the S&P 500 index
Is Allarity Therapeutics in the NASDAQ 100?
No, Allarity Therapeutics is not included in the NASDAQ 100 index
Is Allarity Therapeutics in the Dow Jones?
No, Allarity Therapeutics is not included in the Dow Jones index
When was Allarity Therapeutics the previous earnings report?
No data
When does Allarity Therapeutics earnings report?
Next earnings report date is not announced yet